Evidence map›Paper›PMID 34292617›Full record

ArticleJournal of medical virology2021

Evolution trace of SARS-CoV-2 from January 19 to March 12, 2020, in the United States.

Ziying Lin, Hua Qing, Rui Li, Lei Zheng, Huipeng Yao

Abstract read
In one paragraph

Article in Journal of medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ziying LinCollege of Life Science, Sichuan Agriculture University, Ya'an, China.
Hua QingCollege of Life Science, Sichuan Agriculture University, Ya'an, China.
Rui LiCollege of Life Science, Sichuan Agriculture University, Ya'an, China.
Lei ZhengSichuan University, Chengdu, China.
Huipeng YaoCollege of Life Science, Sichuan Agriculture University, Ya'an, China.ORCID 0000-0001-5078-6492

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a kind of human betacoronavirus, SARS-CoV-2 has endangered globally public health. As of January 2021, the virus had resulted in 2,209,195 deaths. By studying the evolution trend and characteristics of 265 SARS-CoV-2 strains in the United States from January to March, it is found that the strains can be divided into six clades, USA clade-1, USA clade-2, USA clade-3, USA clade-4, USA clade-5, and USA clade-6, in which US clade-1 may be the most ancestral clade, USA clade-2 is an interim clade of USA clade-1 and USA clade-3, the other three clades have similar codon usage pattern, while USA clade-6 is the newest and most adaptable clade. Mismatch analysis and protein alignment showed that the evolution of the clades arises from some special mutations in viral proteins, which may help the strain to invade, replicate, transcribe and so on. Compared with previous research and classifications, we suggest that clade O in GISAID should not be an independent clade and Wuhan-Hu-1 (EPI_ISL_402125) should not be an ancestral reference sequence. Our study decoded the evolutionary dynamic of SARS-CoV-2 in the early stage from the United States, which give some clues to infer the current evolution trend of SARS-CoV-2 and study the function of viral mutational protein.

Indexed as

Evolution, MolecularBayes TheoremCOVID-19HumansMutationPhylogenyPrincipal Component AnalysisSARS-CoV-2Sequence AlignmentUnited StatescladecoronavirusevolutionSARS-CoV-2

Identifiers

PMID34292617
PMCPMC8426869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.